The Foundation for Angelman Syndrome Therapeutics (FAST) announced today that the non-profit organization has entered into an exclusive global collaborative research and development agreement with the ...

EAST SETAUKET, NY, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced an agreement with the Foundation for Angelman Syndrome Therapeutics (FAST) to ...

October 17, 2023—The Foundation for Angelman Syndrome Therapeutics (FAST) announced today that the non-profit organization has entered into an exclusive global collaborative research and development ...

Downers Grove, Ill., Feb. 22, 2018 (GLOBE NEWSWIRE) -- FAST (Foundation for Angelman Syndrome Therapeutics) announced today the launch of GeneTx Biotherapeutics LLC (GeneTx), a subsidiary of FAST, for ...

ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that ...

AUSTIN, Texas, June 4, 2024 /PRNewswire/ — The Foundation for Angelman Syndrome Therapeutics (FAST) announced the establishment of an associated drug development accelerator called AS 2 Bio Inc. The ...

NOVATO, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE) today announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its investigational antisense ...

MIAMI--(BUSINESS WIRE)--Biorasi, a leading global full-service contract research organization (CRO), has announced the appointment of Jimmy El Hokayem, Ph.D., head of the company’s Neurology and ...

GeneTx has a worldwide license agreement and research collaboration with Texas A&M, under which it hopes to develop and commercialize an antisense treatment for Angelman syndrome. (Dominik Moser) () ...

An advanced open-source digital platform developed by QUT researchers is being used to build a patient registry aimed at improving outcomes and health service provision for children and adults around ...